Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsTargeted Therapy in Biliary Tract CancersGenetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapiesIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesOptimum chemotherapy for the management of advanced biliary tract cancerTargeted therapy in biliary tract cancers-current limitations and potentials in the future.Update on the Diagnosis and Treatment of Cholangiocarcinoma.A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trialsTherapeutic options for intrahepatic cholangiocarcinomaChemotherapy and targeted therapy for gall bladder cancer.Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.Molecular genetics and targeted therapeutics in biliary tract carcinoma.Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Targeted agents: how can we improve the outcome in biliary tract cancer?Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Multidisciplinary approaches to intrahepatic cholangiocarcinoma.New and emerging treatment options for biliary tract cancer.Multimodal treatment strategies for advanced hilar cholangiocarcinoma.From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.New Horizons for Precision Medicine in Biliary Tract Cancers.Immunotherapeutic Approaches to Biliary Cancer.Novel investigational therapies for treating biliary tract carcinoma.Current biologics for treatment of biliary tract cancers.Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.Emerging drugs for biliary cancer.New molecular and immunotherapeutic approaches in biliary cancer.Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type
P2860
Q26751224-F38261AC-A507-44A2-AEB9-A05998DEEC95Q26798443-D3951CC8-41F6-4AD2-85F6-6D7F2A9FDC41Q26852049-D1643B94-18C3-41CF-B302-19820C69DD2DQ27002547-7F8F7464-E478-4387-89EA-2E4FECFFC28EQ27010873-7BA94F4E-CA36-469C-A2E7-034E9E453284Q30234532-8DCE7562-C7E2-4359-8DD1-A68009CF2462Q30238895-46277FB2-C883-495E-9DF4-805D4B616C0AQ33411061-4F73165B-5ED8-4712-9A4B-DABA5DCB1C9CQ33556487-381A6B35-B00C-43F9-9688-D58CC740BE07Q33621529-BD512CE8-0CD8-4AA2-8707-37404EBEF34CQ33977171-9B3303B7-725F-4673-A47E-E68F74781281Q33994406-693E8250-A76A-4D11-949C-5A95196BDDA2Q35674607-C308763F-3307-43D3-8ECE-F53715495B1CQ35828499-3DC23260-7F90-4CD0-9B6B-CB7547049FEAQ36488070-93F7F3A7-05D5-4F43-902C-769F6D119892Q36962011-ABF054F0-20AA-47E1-A02B-222B54E0671CQ37017110-95A4D52C-BAB7-46E8-A6B7-6DC4A7C22A2DQ37584590-9B98B364-49CD-4A69-91C9-4081DB40E23BQ37588461-DCD08090-A39C-4847-B239-D7D64FE9C808Q37719383-EA404FC3-1090-499F-915B-FF9DCF3CF30BQ38130469-9745B9E0-6ABF-46F9-9111-9C2FA2698456Q38160836-00E6E29A-9AE7-47B4-8FB8-F279BAC990C8Q38222988-D3CC1894-BDD5-4152-9E60-4C2CEECE6B85Q38234000-F3A3B3B7-77B8-4E53-80C0-ABA514A15038Q38619219-B6E9F051-52D8-4398-9BFD-15006C9E52A2Q38703148-530DEC9B-BC92-46AB-9EA8-4D22BEED48D1Q38799963-DBBB95AD-3063-47DA-B70B-944E91FAB2F8Q39453572-4CD1C9EA-85AD-4257-8844-B26D3D4406FEQ40352514-86F209B2-CB3C-4078-9C5A-234A8D238D61Q40413628-82BE5A0F-DFA9-4710-862A-DCED15ADF715Q40686537-430DBE6C-A117-434A-B418-2660BF49FEB7Q48126437-D54C0BA5-0DE2-41EF-83D4-BC269FF228E6Q48327823-AE4EA984-767B-4A1B-B785-25D2D9FD1E74Q51327505-40ACBFA2-805F-4981-818A-7CB317ECAEF4Q54476966-50284B19-7B27-408C-BD1E-A57C5E4F32FFQ57111762-A25162CB-4F53-446E-9DA4-56BD52363886
P2860
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@en
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@nl
type
label
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@en
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@nl
prefLabel
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@en
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@nl
P2093
P2860
P356
P1433
P1476
Phase II marker-driven trial o ...... ild-type biliary tract cancer.
@en
P2093
A Jakobsen
J Lindebjerg
L H Jensen
T F Hansen
P2860
P304
P356
10.1093/ANNONC/MDS008
P577
2012-02-23T00:00:00Z